AbbVie (NYSE:ABBV) will report third-quarter ... driven by the outperformance of key products Skyrizi and Rinvoq, the continued strong performance of the neuroscience segment and the expected ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback